Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing therapy for Acinetobacter baumannii.

Anton Y Peleg1

  • 1Division of Infectious Diseases, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. apeleg@bidmc.harvard.edu

Seminars in Respiratory and Critical Care Medicine
|December 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using biofilm-targeting local antibiotics to treat recalcitrant medical device-associated infections: driveline infection as a model.

The Journal of antimicrobial chemotherapy·2026
Same author

Vancomycin-resistant Enterococcus infective endocarditis: A case series and review of the literature.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

cGAS/STING sensing in dendritic cells discriminates between daptomycin sensitive and resistant <i>Staphylococcus aureus</i> clinical isolates.

iScience·2026
Same author

Nanopore sequencing enables highly accurate genotyping and identification of resistance determinants in key nosocomial pathogens.

Microbial genomics·2026
Same author

Multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (CALIPSO): trial protocol.

BMJ open·2026
Same author

AMR-GNN: a multi-representation graph neural network framework to enable genomic antimicrobial resistance prediction.

Nature communications·2026
Same journal

Monographic Issue on New Concepts in Acute Exacerbations of COPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.

Seminars in respiratory and critical care medicine·2026
Same journal

Radiological Approach to Severe Respiratory Infections and Pulmonary Complications in Immunocompromised Patients.

Seminars in respiratory and critical care medicine·2026
Same journal

Two Sides of the Same Smoke: Decoding Respiratory Bronchiolitis-Associated Interstitial Lung Disease and Alveolar Macrophage Pneumonia.

Seminars in respiratory and critical care medicine·2026
Same journal

Role of Vaccination in the Prevention of ECOPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives.

Seminars in respiratory and critical care medicine·2026
See all related articles

Drug-resistant Acinetobacter baumannii infections in intensive care units are a growing threat. This review examines current and emerging therapies, highlighting the urgent need for novel antimicrobials to combat this resilient pathogen.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Microbiology

Background:

  • Acinetobacter baumannii is a resilient gram-negative coccobacillus frequently encountered in intensive care units (ICUs).
  • This pathogen poses a significant challenge due to its increasing resistance to existing antimicrobials, leading to difficult-to-treat hospital-acquired infections.
  • The limited pipeline of new antimicrobial agents exacerbates the therapeutic challenges.

Purpose of the Study:

  • To review current therapeutic strategies for Acinetobacter baumannii infections, focusing on clinical human data.
  • To evaluate the efficacy of established antimicrobials (e.g., sulbactam, polymyxins) and newer agents (e.g., tigecycline).
  • To briefly discuss adjunctive measures including pharmacodynamic target attainment and infection control.

Main Methods:

Related Experiment Videos

  • Systematic review of available clinical human data on Acinetobacter baumannii treatment.
  • Exploration of evidence regarding the utility of older and newer antimicrobial agents.
  • Discussion of infection control practices and pharmacodynamic principles.

Main Results:

  • Existing antimicrobials like sulbactam and polymyxins remain important but face resistance challenges.
  • Tigecycline shows potential as a therapeutic option for multidrug-resistant strains.
  • Effective infection control and optimizing drug dosing are crucial adjunctive strategies.

Conclusions:

  • There is an urgent and unmet need for new antimicrobial agents with novel mechanisms of action to combat global drug-resistant Acinetobacter baumannii.
  • A combination of existing therapies, newer agents, and robust infection control measures is essential for managing these infections.
  • Continued research and development of antimicrobials are critical to address the evolving threat of Acinetobacter baumannii.